Supernus Pharmaceuticals Inc (NASDAQ:SUPN) investors are now asking just what’s happening with the company as shares have suddenly skyrocketted out of nowhere, causing a circuit breaker to trip which had halted the stock.
The reason for the surge in share price today? Early reports have indicated that the courts have ruled in favor of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) on two patents in their lawsuit with generic drug makers Actavis. The patents, related to their once-a-day seizure drug Trokendi do not expire until 2029.
Although the exact details of the ruling are not yet available, the market is reacting quite strongly. At approximately 2:30 p.m. ET the stock jumped from $9.54 to $12.30 before being halted for a couple of minutes. After the halt the stock continued to surge, hitting a high of $14.59 at one point. Since then shares have pulled back somewhat. The stock is up 31.89% or $3.23 following the news, hitting $13.36 per share. About 979,195 shares traded hands or up 52.40% from the average. SUPN has declined 40.27% since July 1, 2015 and is currently downtrending. It has underperformed the S&P500 by 31.40%.
The institutional sentiment decreased to 1.43 in Q2 2015. It’s down 0.93, from 2.36 in 2015Q2. The ratio fall, as 17 funds sold all their Supernus Pharmaceuticals Inc shares they owned while 58 reduced their positions. 34 funds bought stakes while 73 increased their total positions. Institutions now own 45.14 million shares which is 6.22% more than the previous share count of 42.49 million in 2015Q2.
Nea Management Company Llc holds 7.06% of its total portfolio in Supernus Pharmaceuticals Inc, equating to 7.64 million shares. Healthinvest Partners Ab owns 782,746 shares representing 6.5% of their total US portfolio. Moreover, Kopp Investment Advisors Llc has 5.51% of their total portfolio invested in the company, equating to 729,960 shares. The Illinois-based Murphy Michael R has a total of 4.96% of their portfolio invested in the stock. Opaleye Management Inc., a Massachusetts-based fund reported 460,000 shares owned.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $687.59 million. The Firm focuses on developing and commercializing products for the treatment of central nervous system diseases. It has 59.2 P/E ratio. The Firm launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR.